Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.74 +0.03 (+0.11%)
Official Closing Price Updated: 1:10 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,629,905
Open 26.59
Bid (Size) 26.77 (2)
Ask (Size) 26.78 (17)
Prev. Close 26.71
Today's Range 26.38 - 26.77
52wk Range 24.48 - 31.54
Shares Outstanding 5,606,688,356
Dividend Yield 6.28%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund: 
Via Benzinga
Topics ETFs
This Is What Whales Are Betting On Pfizer
Via Benzinga

Performance

YTD
-10.06%
-10.06%
1 Month
+2.18%
+2.18%
3 Month
-8.77%
-8.77%
6 Month
-5.71%
-5.71%
1 Year
-5.88%
-5.88%

More News

Read More
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Via Benzinga
Got $500? This Top Dividend ETF Is a Great Buy After Its Recent Sell-Off.
Via The Motley Fool
Topics ETFs
Stocking Stuffers for Income Investors: 3 Ultra-High-Yield Dividend Stocks to Buy Before the End of 2024
Via The Motley Fool
From Uncertainty to Strength: Navigating Life with Cervical Cancer
Via Brandpoint
Pfizer: Guidance Reaffirmed, Nice Yield. What's Not To Like?
Via Talk Markets
Topics Stocks / Equities
Pfizer Just Reassured Investors, but Is the Stock a Buy?
Via The Motley Fool
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Via The Motley Fool
The Stock Market Is Historically Pricey: Here's How I'm Positioning My Portfolio for 2025
Via The Motley Fool
My Top 10 Stocks to Buy for 2025
Via The Motley Fool
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Via Benzinga
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?
Via The Motley Fool
Pfizer Sparks Analyst Cheer With 2025 Guidance: Retail Maintains Extremely Bullish Stance
Via Stocktwits
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Via Investor's Business Daily
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Via FinancialNewsMedia
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy
Via Investor's Business Daily
3 of the Safest Ultra-High-Yield Dividend Stocks to Buy in 2025
Via The Motley Fool
What's Going On With CVS Health, UnitedHealth And Cigna Group Shares?
Via Benzinga
Topics Government
Exposures Political
Stock Of The Day: Is Pfizer About To Break Out? Expect A New Uptrend If Resistance Breaks
Via Benzinga
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
Via Benzinga
Topics Economy
Exposures Interest Rates
Pfizer Does Not Anticipate Material Changes To US Vaccine Policy From The Incoming Administration In 2025
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.